Skip to content

The effect of sumac powder in type 2 diabetic patients

The effect of sumac powder on total antioxidant capacity (TAC), malondialdehyde (MDA), high sensitivity c-reactive protein (hsCRP),glycemic status, apolipoprotein B, apolipoprotein A-I and paraoxonase in type 2 diabetic patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201201172709N24
Enrollment
66
Registered
2012-03-03
Start date
2012-04-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetese melitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: intervention group : sumac supplement, 3 gram per day and during 3 months. Intervention 2: control group : lactose supplement, 2 grams per day and during 3 months.
Treatment - Drugs
intervention group : sumac supplement, 3 gram per day and during 3 months

Sponsors

Vive-chancellor for Research, Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : Non-insulin dependent diabetic patients with type 2 diabetes that is diagnosed by a physician, Endocrinologist ; Diabetes duration of at least 2 year ; 20-60 ages ; Hb A1c :6-8% ; Lack of antioxidant supplements such as selenium, zinc, beta carotene, and ... At least 3 months before the study ; not smoking and alcohol ; a willingness to cooperate with exclusion criteria : Patient unwillingness to continue with the plan ; changes in type or dose of medication ; Changes in diet or physical activity every day ; taking any antioxidant supplements ; taking less than 80% of supplements given to patients at baseline (the compaliance lower than %80) ; Recent receive insulin ; pregnancy and lactation ; renal , hepatic , thyroid diseases and anemia ; hypersensitivity to the drug

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fasting blood sugar. Timepoint: before & after intervention (3 months later). Method of measurement: glucose oxidase method.;Hb A1C. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry.;Insulin. Timepoint: before & after intervention (3 months later). Method of measurement: IRMA.;Insulin resistance. Timepoint: before & after intervention (3 months later). Method of measurement: insulin × glucose / 22.5.;Apo A. Timepoint: before & after intervention (3 months later). Method of measurement: immunotorbidometry.;Apo B. Timepoint: before & after intervention (3 months later). Method of measurement: immunotorbidometry.;Apo B/Apo A-I. Timepoint: before & after intervention (3 months later). Method of measurement: ratio.;High-sensitivity C-Reactive Protein. Timepoint: before & after intervention (3 months later). Method of measurement: ELISA kitt.;Total antioxidant capacity. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry (FRAP).;Malondealdehyde. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry.;Paraoxonase. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry.

Secondary

MeasureTime frame
-. Timepoint: -. Method of measurement: -.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farzad Shidfar

School of Public Health of Tehran University of Medical Sciences

farzadshidfar@yahoo.com+98 21 8877 9118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026